A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors (NCT06253130)

🧪 Interventions in This Study

• IMP1734 (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (57 Sites)

Showing the first 25 of 57 sites.

• The University of Arizona Cancer Center — Tucson, Arizona
• University of Arkansas Winthrop P. Rockefeller Cancer Institute — Little Rock, Arkansas
• Hoag Health Center Irvine — Irvine, California
• University California Irvine — Irvine, California
• Sharp Memorial Hospital — San Diego, California
• University of California San Francisco (UCSF) — San Francisco, California
• Sarah Cannon Research Institute Health One — Denver, Colorado
• Smilow Cancer Hospital at Yale New Haven — New Haven, Connecticut
• Advent Health Research Institute — Celebration, Florida
• Sylvester Comprehensive Cancer Center — Miami, Florida
• University of Michigan Rogel Cancer Center — Ann Arbor, Michigan
• Karmanos Cancer Institute — Detroit, Michigan
• Henry Ford Health — Detroit, Michigan
• University of Minnesota-Clinical Research Unit — Minneapolis, Minnesota
• Washington University - Siteman Cancer Center — St Louis, Missouri
• John Theurer Cancer Center — Hackensack, New Jersey
• Cayuga Medical Center — Ithaca, New York
• Lifespan Cancer Institute — Providence, Rhode Island
• Medical University of South Carolina (MUSC) - Hollings CC — Charleston, South Carolina
• West Cancer Center & Research Institute — Germantown, Tennessee
• Sarah Cannon Research Institue Oncology — Nashville, Tennessee
• START - South Texas Accelerated Research Therapeutics — San Antonio, Texas
• START Mountain Region — West Valley City, Utah
• Scientia Clinical Research Ltd — Randwick, New South Wales
• Mater Cancer Care Centre, Mater Misericordiae Limited — South Brisbane, Queensland

📞 Contact the Study Coordinator

Phone: (212) 540-4923

Email: parpitrial@eikontx.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Advanced Solid Tumor

• Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression — Iowa City, Iowa
• A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors — Glendale, California
• QTX3046 in Patients With KRAS G12D Mutations — Grand Rapids, Michigan
• A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors — Houston, Texas
• First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer — Fullerton, California
• A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors — San Antonio, Texas

Explore by condition: All Advanced Solid Tumor clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.